Bristol Myers Squibb CO Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NYSE
State Street Corporation has updated its beneficial ownership filing for Bristol-Myers Squibb, reporting a significant aggregate holding.
NYSE
Vanguard Capital Management disclosed a beneficial ownership of 153,108,018 shares, representing 7.49% of Bristol-Myers Squibb's common stock as of March 31, 2026.
NYSE
The Vanguard Group has amended its Schedule 13G filing for Bristol-Myers Squibb Co, reporting 0% beneficial ownership due to an internal realignment.
NYSE
JPMorgan Chase & Co. has filed an amendment to its Schedule 13G, disclosing a 4.0% beneficial ownership stake in Bristol-Myers Squibb Company as of September 30, 2025.
NYSE
JPMorgan Chase & Co. has filed a Schedule 13G, revealing a beneficial ownership of 5.1% in Bristol-Myers Squibb Company as of March 31, 2025.
NYSE
SCHEDULE 13G/A: BlackRock Discloses 7.1% Stake in Bristol Myers Squibb
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 7.1% beneficial ownership stake in Bristol Myers Squibb Co. as of March 31, 2025.
NYSE
Bristol Myers Squibb Company and its subsidiary Celgene Corporation have filed an amended Schedule 13G, disclosing a continued passive beneficial ownership of 1.9% in Celularity Inc.'s Class A Common Stock.
NYSE
Bristol-Myers Squibb Company has filed an amended Schedule 13G, reporting a 2.06% passive beneficial ownership stake in Compugen Ltd. as of December 31, 2024.
NYSE
Bristol Myers Squibb Company has filed an amended Schedule 13G, reporting a 1.64% beneficial ownership stake in Q32 Bio Inc. as of December 31, 2024.